Incanthera PLC Notice of AGM

RNS Number : 5213F

Incanthera PLC

25 September 2024

 

 

 

 

 

 

                                                                                                            25 September 2024

 

Incanthera plc

("Incanthera" the "Company")

 

Notice of Annual General Meeting 2024 and Posting of Annual Report and Accounts

 

Incanthera plc (AQSE: INC), the company focused on innovative technologies in dermatology and oncology, confirms that the Annual Report and Accounts for the year ended 31 March 2024, and the Notice of Annual General Meeting ("AGM") with accompanying Form of Proxy has been posted to shareholders and to the Company's website today.

 

These documents are available, in electronic form, for download on the Company's website: https://www.incanthera.com/media/144901/Incanthera-2024-NoM.pdf

https://www.incanthera.com/media/144904/Incanthera-ARA-2024.pdf

 

Incanthera's AGM will be held at 11:00 am on Thursday,17 October 2024 at the offices of Gateley Plc, 1 Paternoster Square, London EC4M 7DX.

 

In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform.   However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible.

 

Shareholders are invited to submit any questions for the Board to consider. Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 16 Oct 2024, 09:00 BST, or submitted at any time during the AGM itself.

 

Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link:

 

https://www.investormeetcompany.com/incanthera-plc/register-investor

 

 

Investors who already follow INCANTHERA PLC on the Investor Meet Company platform will automatically be invited.

 

The Board will respond to key questions during the meeting and will provide such answers on its website thereafter. 

 

 

For further information please contact:

 

Incanthera plc www.incanthera.com   Tim McCarthy, Chairman [e-mail]   Simon Ward, Chief Executive Officer [e-mail]   Suzanne Brocks, Head of Communications [e-mail]	[phone]     [phone]     [phone]
Aquis Exchange Corporate Adviser:  Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes	[phone]
Broker:  Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	[phone]/51

 

Notes to Editors

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                   

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXPPUGABUPCPGC